Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Healthtrust
Moodys
Farmers Insurance
Merck
Boehringer Ingelheim
Deloitte
Julphar

Generated: June 24, 2018

DrugPatentWatch Database Preview

NAVANE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Navane patents expire, and when can generic versions of Navane launch?

Navane is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in NAVANE is thiothixene hydrochloride. There are six drug master file entries for this compound. Additional details are available on the thiothixene hydrochloride profile page.
Summary for NAVANE
Drug patent expirations by year for NAVANE
Synonyms for NAVANE
(9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide
(9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
(E)-Thiothixene
(Z)-N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulfonamide
(Z)-Thiothixene
{2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene
2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene
3313-26-6
5591-45-7
7318FJ13YJ
9H-Thioxanthene-2-sulfonamide, N, {N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-,} (Z)-
9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-[3-(4-methyl- 1-piperazinyl)propylidene]-, (9Z)-
9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-
AC1LJ0FG
AK397466
AKOS015850761
AN-18958
AOB5787
AS-16925
BDBM78576
BIDD:PXR0153
CCG-205218
CHEBI:9571
CHEMBL1201
cid_941651
cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide
cis-Thiothixene
CP 12252-1
CP-12,252-1
CP-12,252-1 base
CPD000058396
CS-7959
D00374
D0E0LQ
DB01623
DTXSID2091542
GFBKORZTTCHDGY-UWVJOHFNSA-N
GTPL212
HMS2230F08
HY-108324
Lopac0_001144
LS-153666
LS-153667
MFCD00079574
MLS000028463
MLS006010662
N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thiaxanthene-2-sulfonamide
N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide
N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide
N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-9H-thioxanthene-2-sulfonamide #
N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide
N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide
N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide
Navan
Navane (TN)
Navaron
NCGC00162353-01
NSC-108165
NSC108165
Opera_ID_626
Orbinamon
P 4657B
P-4657 B
P-4657-B
P-4657A
P-4657B
PDSP1_000038
PDSP1_000625
PDSP1_000626
PDSP2_000038
PDSP2_000622
PL001477
SAM002589997
SCHEMBL34305
SMR000058396
T15560
thiothixene
Thiothixene (USP)
Thiothixene (Z)
Thiothixene [USAN:BAN]
THIOTHIXENE HCL
Thiothixene hydrochloride
Thiothixene Hydrochloride (base)
Thiothixene, meets USP testing specifications
Thiothixene, United States Pharmacopeia (USP) Reference Standard
Thiothixine
Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-
Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (E)-
Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)-, (Z)-
Tiotixene
Tiotixene (JAN)
Tiotixeno
Tiotixeno [INN-Spanish]
Tiotixenum
Tiotixenum [INN-Latin]
trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide
UNII-7318FJ13YJ
UNII-LF886533UR component GFBKORZTTCHDGY-UWVJOHFNSA-N
ZINC30690433

US Patents and Regulatory Information for NAVANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer NAVANE thiothixene CAPSULE;ORAL 016584-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer NAVANE thiothixene hydrochloride INJECTABLE;INJECTION 016904-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer NAVANE thiothixene CAPSULE;ORAL 016584-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer NAVANE thiothixene hydrochloride INJECTABLE;INJECTION 016904-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
UBS
Chubb
Mallinckrodt
Covington
US Department of Justice
Daiichi Sankyo
US Army
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.